Facebook
X
LinkedIn
Forward
An Evolving Standard of Care in Chronic Lymphocytic Leukemia: Patient Perspectives and Clinical Insights on Novel Therapeutic Strategies Across the Disease Continuum
Recent advances in the use of targeted therapies have transformed the CLL treatment landscape, creating new opportunities as well as greater complexity in clinical decision-making. In this activity, two leading CLL specialists review the latest evidence and therapeutic strategies, emphasizing the importance of shared decision-making and individualized care. The program features real, videorecorded patient vignettes that highlight the perspectives and experiences of individuals living with CLL, offering powerful insights into how treatment choices affect patients’ lives. Through these voices and expert discussion, clinicians will gain practical guidance to optimize outcomes and personalize therapy for their own patients.
Throughout the activity, the faculty reference several resources developed by the CLL Society for clinicians as well as individuals living with the disease. Links to those materials can be found below:
- The CLL Medicine Cabinet
- Test Before You Treat Resources
- CAR T Cell Therapy Patient Primer
- Clinician Resource Library
Target Audience
This activity is intended for medical and hematologic oncologists, hematolgy-oncology fellows, oncology advanced practice professionals (NPs/PAs), oncology nurses (RNs), and oncology pharmacists who care for patients with CLL.
Learning Objectives
Upon completion of this activity, the learner should be able to:
- Appraise the most recent clinical practice guidelines in treatment-naïve (TN) CLL to reduce unwarranted practice variations and improve long-term outcomes for patients.
- Discuss the therapeutic implications of BTK resistance mutations in CLL to optimize sequencing of covalent and noncovalent BTK inhibitors in fixed-duration (FD) and treat-to-progression (TTP) strategies across the disease continuum.
- Define the evolving role of covalent BTK inhibitors and CAR T-cell therapy in CLL to guide clinical decision-making and enhance translation of treatment advances into practice.
- Evaluate patient priorities among CLL treatment attributes including efficacy, tolerability, and mode/frequency of administration to optimize patient satisfaction with treatment and quality of life (QoL) outcomes.
- Recognize differences in the occurrence of toxicities among novel agents and combinations used in the management of TN and progressive CLL to improve monitoring and management of treatment-related adverse events (AEs) for individual patients.
An Evolving Standard of Care in Chronic Lymphocytic Leukemia: Patient Perspectives and Clinical Insights on Novel Therapeutic Strategies Across the Disease Continuum
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jennifer Woyach, MD (Moderator)
D Warren Brown Chair of Leukemia Research
Professor and Director, Division of Hematology
Co-Director, Leukemia and Hematologic Malignancies Research Program
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine | Harvard Medical School
Leader, Lymphoma Program, Dana-Farber/Harvard Cancer Center
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
- Dr. Woyach faculty for this educational activity, has the following relevant financial relationships:
- Consultant: AbbVie Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Merck & Co., Inc.; and Newave Pharmaceutical Inc.
- Advisory Board: AbbVie Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Merck & Co., Inc.; and Newave Pharmaceutical Inc.
- Dr. Davids faculty for this educational activity, has the following relevant financial relationships:
- Consultant: AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene; Bristol Myers Squibb Company; Galapagos; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc; MEI Pharma, Inc.; Nuvalent; and Schrödinger, Inc.
- Research Support: Ascentage Pharma; AstraZeneca; MEI Pharma, Inc.; and Novartis Pharmaceuticals Corporation
- Royalties: UpToDate
- Chloe Cianatasio, MS, planner for this educational activity, has no financial relationships.
- Thomas Mitchell, MSW, LSW planner for this educational activity, has no financial relationships.
- Taylor Wallace, planner for this educational activity, has no financial relationships.
- Jessica Rucki planner for this educational activity, has no financial relationships.
- Brian Moss planner for this educational activity, has no financial relationships.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Efficient LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Price
- Estimated time to complete the activity 1.0 hrs.
- Mechanism for learner to contact the accredited provider. Example: For additional information about the accreditation of this activity, please visit https://partnersed.com.
- Computer system hardware/software requirements \
Required Hardware/software
The Learning Management System requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content